EHRs, like microscopes, might require physicians to change perspective

Lloyd B. Minor, the dead of Stanford University School of Medicine, equated problems harnessing the positives of EHR with the microscope. It took 70 years for that game-changing tool to lead to scientific breakthroughs—a delay that might have to do as much with the user as the instrument itself.

Microscope historian Clara Sue Ball ties this delay to quality difficulties and scientists’ inability to fully comprehend the instrument’s potential.

“Ball’s hypothesis reminds me of the current state of electronic health records (EHRs),” Minor wrote in Fortune. Today, EHRs digitally document nearly all patient care delivered in the United States. This achievement should be accelerating an era of data-driven medicine. Yet, after a decade of widespread use and an immense volume of data gathered, modern EHRs have yet to deliver on their potential.”

He argues physicians need to rethink how they interface with EHRs—that they should “should resist the temptation to solely focus on the technology behind these systems.”

Read Minor’s full remarks at the link below:

""
Nicholas Leider, Managing Editor

Nicholas joined TriMed in 2016 as the managing editor of the Chicago office. After receiving his master’s from Roosevelt University, he worked in various writing/editing roles for magazines ranging in topic from billiards to metallurgy. Currently on Chicago’s north side, Nicholas keeps busy by running, reading and talking to his two cats.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.